NSC 207895

Confirm delete?

NSC 207895

Zoom

Cat No: 27949

Biochemicals - More Biochemicals

NSC 207895 is an inhibitor of the p53-binding protein MDMX.{48617} It decreases MDMX promoter activity in a reporter assay using HT-1080 cells in a concentration-dependent manner. NSC 207895 (5 µmol/L) decreases the expression and protein levels of MD...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-(4-methyl-1-piperazinyl)-7-nitro-2,1,3-benzoxadiazole, 3-oxide

Correlated keywords:

NSC207895 p 21 53 HT1080 CDKN 1 MCF7 proapoptotic PIG 3 NSC179940 XI006

Product Overview:
NSC 207895 is an inhibitor of the p53-binding protein MDMX.{48617} It decreases MDMX promoter activity in a reporter assay using HT-1080 cells in a concentration-dependent manner. NSC 207895 (5 µmol/L) decreases the expression and protein levels of MDMX and increases the expression of the p53 target gene CDKN1 (p21) in MCF-7 cells overexpressing MDMX. It also increases the expression of the pro-apoptotic genes PUMA, Bax, and PIG3. NSC 207895 (5 µmol/L) induces apoptosis and decreases cell viability in MCF-7 cells in a p53-dependent manner. It also induces p53-independent apoptosis in wild-type, mutated, and truncated p53 Ewing sarcoma cell lines (IC50s = 98.9-1,613, 236-299, and 121-396 nM, respectively) selectively over wild-type and p53-null osteosarcoma cells (IC50s = 3,690-5,416 and 2,143 nM, respectively).{48617,48618}

Size	1 mg
Shipping	dry ice
CAS Number	58131-57-0
Molecular Formula	C₁₁H₁₃N₅O₄
SMILES	CN1CCN(C2=CC=C([N+]([O-])=O)C3=NO[N+]([O-])=C32)CC1
Molecular Weight	279,3
Formulation	A solid
Purity	≥98%
Custom Code	2933.59
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.